Profile data is unavailable for this security.
About the company
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
- Revenue in GBP (TTM)49.78k
- Net income in GBP-1.78m
- Incorporated2000
- Employees14.00
- LocationValiRx PLCMediCity Nottingham, D6 Thane RoadNOTTINGHAM NG90 6BHUnited KingdomGBR
- Phone+44 11 5784 0025Fax+44 20 3008 4415
- Websitehttps://www.valirx.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Shortwave Life Sciences PLC | 45.70k | -256.99k |
| Roquefort Therapeutics PLC | 0.00 | -882.45k |
| ValiRx Plc | 49.78k | -1.78m |
| N4 Pharma PLC | 7.07k | -1.07m |
| TheraCryf PLC | 0.00 | -2.01m |
| Ovoca Bio PLC | 0.00 | 65.12k |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m |
| Futura Medical PLC | 7.93m | -6.29m |
| OptiBiotix Health PLC | 1.15m | -191.00k |
| IXICO PLC | 6.53m | -1.65m |
| Genflow Biosciences PLC | 0.00 | -1.80m |
